Cis-platinum vestibular toxicity.
Cis-diamminedichloroplatinum has been proven to be an effective neoplastic agent. Nephrotoxicity and ototoxicity are two prominent side effects of this drug. Investigation of ototoxicity has been limited to auditory function. This report details the first known case of vestibular toxicity following platinum therapy. In addition, a prospective vestibular testing program is reported.
D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D034381:Hearing Loss / Q000139:chemically induced*; D006315:Hearing Loss, Functional / Q000139:chemically induced*; D006801:Humans; D008297:Male; D037981:Neck Dissection; D011879:Radiotherapy Dosage; D014067:Tonsillar Neoplasms / Q000628:therapy*; D014724:Vestibular Function Tests; D014722:Vestibule, Labyrinth / Q000187:drug effects*
D002945:Cisplatin